MTVA READ THE FULL MTVA RESEARCH REPORT Business Update Compelling Results for DA-1241 in Phase 2a MASH Trial On December 18, 2024, MetaVia Inc. (NASDAQ:MTVA) announced positive topline results from ...

DA-1241 100mg showed statistically significant reductions in ALT levels at weeks 4 and 8 (p=0.0159 and p=0.0342, respectively) and a near statistically significant reduction (p=0.0506) at week 16 ...

(RTTNews) - MetaVia Inc. (MTVA), Wednesday announced positive 16-week results from the two-part Phase 2a clinical trial of DA-1241 in patients with presumed metabolic dysfunction-associated ...

Part 1 of this Phase 2a trial is exploring DA-1241, a novel G-Protein-Coupled Receptor 119, or GPR119, agonist compared to placebo, while Part 2 is investigating the efficacy of DA-1241 in ...

MetaVia Inc. is developing DA-1241 as a treatment for metabolic dysfunction-associated steatohepatitis (MASH; formerly NASH). DA-1241 is a novel chemical entity that selectively activates GPR119 ...

"Completion of patient dosing in the Phase 2a clinical trial of DA-1241, in patients with presumed MASH, marks an important milestone for this promising cardiometabolic asset, bringing us one step ...

DA-1241 100mg showed statistically significant reductions in ALT levels at weeks 4 and 8 (p=0.0159 and p=0.0342, respectively) and a near statistically significant reduction (p=0.0506) at week 16 ...

NeuroBo Pharmaceuticals (NRBO) announced the completion of the last patient last visit in its two-part, Phase 2a clinical trial evaluating the efficacy and safety of DA-1241, a novel G-Protein ...

On December 18, 2024, MetaVia Inc. (NASDAQ:MTVA) announced positive topline results from the 16-week Phase 2a clinical trial of DA-1241 in patients with presumed metabolic dysfunction-associated ...

Topline Data Readout From Part 1 and Part 2 Expected in December 2024 ...